View Older Stories View More Recent Stories
-
Berenberg Reiterates Hold Rating on Pfizer (PFE)
-
Citi on Pfizer (PFE)
-
U.S. probing GSK's tip about timing of Pfizer (PFE) vaccine - WSJ
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Active options: PFE COIN BABA INTC F HOOD GOOGL MU MSFT MARA WMT
-
Will Pfizer step into the obesity ring? Wolfe Research answers
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Arvinas Inc. (ARVN) and Pfizer (PFE) Announce Positive Topline Results from Phase 3 VERITAC-2 Trial
-
CDC Plans Large Study Into Potential Connections Between Vaccines and Autism - Reuters
-
Pfizer (PFE) Appoints James List as Chief Internal Medicine Officer
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
Pfizer (PFE) PT Lowered to $30 at Bernstein; 'We Need to See More'
-
Pfizer (PFE) Announces New Chief Medical Officer
-
Summit Therapeutics (SMMT) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
-
Clorox (CLX) gains 2.7% on new virus concerns
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
Pfizer (PFE) Will End Global Development and Commercialization of Beqvez - Nikkei
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
Pfizer (PFE) stock: What could right the ship according to Wolfe
-
RFK, Jr. said confirmed
-
Pfizer (PFE) Reports TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
House Speaker Johnson Says He Believes The White House Is Considering Exemptions To Reciprocal Tariffs Including Autos And Pharmaceuticals - Reuters
-
Pfizer (PFE): U.S. FDA Approves Pfizer’s ADCETRIS Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
Pfizer (PFE) PT Raised to $34 at Jefferies
-
Pfizer (PFE) and Astellas PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of la/mUC
-
Pfizer (PFE) PT Lowered to $32 at Goldman Sachs
-
Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
-
Pfizer (PFE) call put ratio 2.2 calls to 1 put with focus on June 28 calls
-
Pfizer's (PFE) BRAFTOVI Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
-
Pfizer (PFE) call put ratio 1 call to 1 put into quarter results
-
Moderna stock rises following RFK Jr's comments
-
Pfizer (PFE) to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
-
Pfizer (PFE) Said To Avoid Challenge From Activist Starboard For Now - Bloomberg
-
Pfizer (PFE) Intends To Sell About 700M Haleon (HLN) Shares
-
Pfizer (PFE) CEO: "all in" on obesity drug development - JPM Healthcare Conference
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Pfizer's (PFE) Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
-
Pfizer (PFE) call put ratio 2.8 calls to 1 put as share price up 1.1%
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
2025 Biopharma sector outlook
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Sangamo Therapeutics (SGMO) to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
-
Pfizer (PFE) Announces FDA Approval of BRAFTOVI Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
-
Pfizer (PFE) PT Lowered to $32 at Truist Securities
-
Bernstein on Pfizer's (PFE) FY2025 Guide: 'Nothing Too Surprising, But First Guide on Part D IRA Impact'
